BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:Matthew Galsky\, M.D. | Pamela Hearn Isom Lectureship in Honor
  of Eugene P. Frenkel\, M.D.
X-WR-TIMEZONE:Central Time (US & Canada)
BEGIN:VEVENT
DTSTAMP:20260906T124753Z
UID:tag:localist.com\,2008:EventInstance_53454091020323
DTSTART:20260724T170000Z
DTEND:20260724T180000Z
DESCRIPTION:"The Evolving Landscape of Urothelial Cancer Treatment"\n\nSpea
 ker:\n\nMatthew Galsky\, M.D.\nLillian and Howard Stratton Professor of Me
 dicine\nDirector of Genitourinary Medical Oncology\nDivision of Hematology
  & Medical Oncology\nIcahn School of Medicine at Mount Sinai\nDeputy Direc
 tor\, Mount Sinai Tisch Cancer Center\n\nAbout Matthew Galsky:\n\nDr. Gals
 ky earned his medical degree from Tufts University School of Medicine\, co
 mpleted an internal medicine residency at Beth Israel Deaconess Medical Ce
 nter/Harvard Medical School\, and a medical oncology fellowship at Memoria
 l Sloan Kettering Cancer Center\, where he served as Chief Fellow.\n\nA me
 dical oncologist specializing in bladder\, prostate\, kidney\, and testicu
 lar cancers\, Dr. Galsky has built an internationally recognized research 
 program focused on developing new treatments for genitourinary malignancie
 s and advancing precision medicine approaches for patients with urothelial
  carcinoma. His work combines clinical trials\, translational research\, a
 nd biomarker discovery to better understand why some patients respond to t
 herapy while others develop resistance.\n\nHis current research focuses on
  the biologic drivers of luminal urothelial cancer\, particularly the PPAR
 γ signaling pathway. His team and collaborators have helped establish PPA
 Rγ as a key regulator of luminal differentiation in normal urothelium and
  a potential therapeutic target in bladder cancer\, where genomic studies 
 have identified enrichment of PPARγ amplifications and RXRα mutations. D
 r. Galsky has been involved in the clinical development of FX-909\, a firs
 t-in-class PPARγ inverse agonist designed to suppress both ligand-induced
  and basal transcriptional activity. Early clinical findings presented at 
 the 2026 ASCO Genitourinary Cancers Symposium demonstrated evidence of tar
 get engagement and preliminary antitumor activity in heavily pretreated pa
 tients with advanced urothelial carcinoma\, supporting ongoing studies aim
 ed at refining patient selection and expanding the role of PPARγ-targeted
  therapy in bladder cancer.
LOCATION:
SUMMARY:Matthew Galsky\, M.D. | Pamela Hearn Isom Lectureship in Honor of E
 ugene P. Frenkel\, M.D.
URL;VALUE=URI:https://events.utsouthwestern.edu/event/hematology-oncology-g
 rand-rounds-matthew-galsky
CATEGORIES:Grand Rounds
CATEGORIES:Continuing Education (CE)
END:VEVENT
END:VCALENDAR